Literature DB >> 27615400

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Justine V Cohen1, Hussain Tawbi2, Kim A Margolin3, Ravi Amravadi4, Marcus Bosenberg1, Priscilla K Brastianos5, Veronica L Chiang1, John de Groot6, Isabella C Glitza2, Meenhard Herlyn7, Sheri L Holmen8, Lucia B Jilaveanu1, Andrew Lassman9, Stergios Moschos10, Michael A Postow11, Reena Thomas12, John A Tsiouris13, Patrick Wen14, Richard M White15, Timothy Turnham16, Michael A Davies2, Harriet M Kluger1.   

Abstract

Melanoma central nervous system metastases are increasing, and the challenges presented by this patient population remain complex. In December 2015, the Melanoma Research Foundation and the Wistar Institute hosted the First Summit on Melanoma Central Nervous System (CNS) Metastases in Philadelphia, Pennsylvania. Here, we provide a review of the current status of the field of melanoma brain metastasis research; identify key challenges and opportunities for improving the outcomes in patients with melanoma brain metastases; and set a framework to optimize future research in this critical area.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  brain metastasis; clinical trials; experimental models; leptomeningeal disease; tumor microenvironment

Mesh：

Year:  2016        PMID： 27615400      PMCID： PMC5398760          DOI： 10.1111/pcmr.12538

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN： 1755-1471            Impact factor:   4.693


  135 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine.

Authors:  Niklas Schaefer; Katja Rasch; Markus Moehlenbruch; Horst Urbach; Moritz Stuplich; Elias Blasius; Bjoern Scheffler; Ulrich Herrlinger; Martin Glas
Journal:  Acta Oncol       Date:  2011-07-08       Impact factor: 4.089

3.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

4.  Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients.

Authors:  Emeline Pape; Eve Desmedt; Fahed Zairi; Marie-Christine Baranzelli; Veronique Dziwniel; François Dubois; Jacques Bonneterre; Laurent Mortier; Emilie Le Rhun
Journal:  In Vivo       Date:  2012 Nov-Dec       Impact factor: 2.155

5.  PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases In Vitro and In Vivo.

Authors:  Heike Niessner; Jennifer Schmitz; Ghazaleh Tabatabai; Andreas M Schmid; Carsten Calaminus; Tobias Sinnberg; Benjamin Weide; Thomas K Eigentler; Claus Garbe; Birgit Schittek; Leticia Quintanilla-Fend; Benjamin Bender; Marion Mai; Christian Praetorius; Stefan Beissert; Gabriele Schackert; Michael H Muders; Matthias Meinhardt; Gustavo B Baretton; Reinhard Dummer; Keith Flaherty; Bernd J Pichler; Dagmar Kulms; Dana Westphal; Friedegund Meier
Journal:  Clin Cancer Res       Date:  2016-06-15       Impact factor: 12.531

6.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

7.  Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Authors:  Marissa N Balak; Yixuan Gong; Gregory J Riely; Romel Somwar; Allan R Li; Maureen F Zakowski; Anne Chiang; Guangli Yang; Ouathek Ouerfelli; Mark G Kris; Marc Ladanyi; Vincent A Miller; William Pao
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

8.  Psychometric validation of the functional assessment of cancer therapy--brain (FACT-Br) for assessing quality of life in patients with brain metastases.

Authors:  Nemica Thavarajah; Gillian Bedard; Liying Zhang; David Cella; Jennifer L Beaumont; May Tsao; Elizabeth Barnes; Cyril Danjoux; Arjun Sahgal; Hany Soliman; Edward Chow
Journal:  Support Care Cancer       Date:  2013-11-28       Impact factor: 3.603

9.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

Review 10.  Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma.

Authors:  Andrea J McKinney; Sheri L Holmen
Journal:  Chin J Cancer       Date:  2011-03
View more
  40 in total

1.  Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Authors:  Gautham Gampa; Shruthi Vaidhyanathan; Jann N Sarkaria; William F Elmquist
Journal:  Pharmacol Res       Date:  2017-06-17       Impact factor: 7.658

Review 2.  Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Authors:  Priscilla K Brastianos; Franziska Maria Ippen; Umbreen Hafeez; Hui K Gan
Journal:  Oncologist       Date:  2018-04-27

3.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Authors:  Harriet M Kluger; Veronica Chiang; Amit Mahajan; Christopher R Zito; Mario Sznol; Thuy Tran; Sarah A Weiss; Justine V Cohen; James Yu; Upendra Hegde; Elizabeth Perrotti; Gail Anderson; Amanda Ralabate; Yuval Kluger; Wei Wei; Sarah B Goldberg; Lucia B Jilaveanu
Journal:  J Clin Oncol       Date:  2018-11-08       Impact factor: 44.544

4.  Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Authors:  Laura J Gardner; Morgan Ward; Robert H I Andtbacka; Kenneth M Boucher; Glen M Bowen; Tawnya L Bowles; Adam L Cohen; Kenneth Grossmann; Ying J Hitchcock; Sheri L Holmen; John Hyngstrom; Hung Khong; Martin McMahon; Marcus M Monroe; Carolyn B Ross; Gita Suneja; David Wada; Douglas Grossman
Journal:  Melanoma Res       Date:  2017-10       Impact factor: 3.599

5.  Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Authors:  Sherise D Ferguson; Shivani Bindal; Roland L Bassett; Lauren E Haydu; Ian E McCutcheon; Amy B Heimberger; Jing Li; Barbara J O'Brien; Nandita Guha-Thakurta; Michael T Tetzlaff; Hussein Tawbi; Michael A Davies; Isabella C Glitza
Journal:  J Neurooncol       Date:  2019-03-07       Impact factor: 4.130

6.  Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.

Authors:  Gautham Gampa; Minjee Kim; Nicholas Cook-Rostie; Janice K Laramy; Jann N Sarkaria; Linda Paradiso; Louis DePalatis; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2018-02-02       Impact factor: 3.922

7.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Authors:  Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long
Journal:  Lancet Oncol       Date:  2017-06-04       Impact factor: 41.316

Review 8.  Case series review of neuroradiologic changes associated with immune checkpoint inhibitor therapy.

Authors:  Na Tosha N Gatson; Mina Makary; Shane P Bross; Joseph Vadakara; Tristan Maiers; Gino J Mongelluzzo; Erika N Leese; Cameron Brimley; Ekokobe Fonkem; Anand Mahadevan; Atom Sarkar; Rajiv Panikkar
Journal:  Neurooncol Pract       Date:  2020-11-29

Review 9.  Foe or friend? Janus-faces of the neurovascular unit in the formation of brain metastases.

Authors:  Imola Wilhelm; Csilla Fazakas; Kinga Molnár; Attila G Végh; János Haskó; István A Krizbai
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-18       Impact factor: 6.200

10.  Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.

Authors:  Lauren E Haydu; Serigne N Lo; Jennifer L McQuade; Rodabe N Amaria; Jennifer Wargo; Merrick I Ross; Janice N Cormier; Anthony Lucci; Jeffrey E Lee; Sherise D Ferguson; Robyn P M Saw; Andrew J Spillane; Kerwin F Shannon; Jonathan R Stretch; Patrick Hwu; Sapna P Patel; Adi Diab; Michael K K Wong; Isabella C Glitza Oliva; Hussein Tawbi; Matteo S Carlino; Alexander M Menzies; Georgina V Long; Alexander J Lazar; Michael T Tetzlaff; Richard A Scolyer; Jeffrey E Gershenwald; John F Thompson; Michael A Davies
Journal:  J Clin Oncol       Date:  2020-01-28       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.